Stresscopins and their uses

Details Stresscopins and their uses Stresscopins and their uses

2007-11-05

2010-11-09

Falk, Anne-Marie (Department: 1632)

Chemistry: molecular biology and microbiology

Vector, per se

C435S325000

Reexamination Certificate

active

07829330

ABSTRACT:
The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.

REFERENCES:
patent: 2003/0036507 (2003-02-01), Vale et al.
patent: 2004/0143095 (2004-07-01), Vale et al.
patent: WO 9700063 (1997-01-01), None
patent: WO0212307 (2002-02-01), None
Wolf et al, (Mol Biol Med, 5(1): 1-2,1999).
Horlick et al, (Protein Expression and Purification, 9, 301-308, 1997).
Bale et al., “Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress,” Nat. Genet., 2000, 24(4):410-414.
Chen et al., “Expression cloning of a human corticotropin-releasing-factor receptor,” Proc. Natl. Acad. Sci. USA, 1993, 90(19):8967-8971.
Coste et al., “Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2,” Nat. Genet., 2000, 24(4):403-409.
Donaldson et al., “Cloning and Characterization of Human Urocortin,” Endocrinology, 1996, 137(5):2167-2170.
Grammatopoulos et al., “A Novel Spliced Variant of the Type 1 Corticotropin-Releasing Hormone Receptor with a Deletion in the Seventh Transmembrane Domain Present in the Human Pregnant Term Myometrium and Fetal Membranes,” Mol. Endocrinol., 1999, 13(12):2189-2202.
Hsu et al., “Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor,” Nat. Med., 2001, 7(5):605-611.
Lewis et al., “Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor,” Proc. Natl. Acad. Sci. U.S.A., 2001, 98(13):7570-7575.
Liaw et al., “Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid,” Endocrinology, 1996, 137(1):72-77.
Reyes et al., “Urocortin II: A Member of the Corticotropin-Releasing Factor (CRF) Neuropeptide Family that is Selectively Bound By Type 2 CRF Receptors,” Proc. Natl. Acad. Sci. USA, 2001, 98(5):2843-2848.
Shibahara et al., “Isolation and sequence analysis of the human corticotropin-releasing factor precurser gene,” EMBO J, 1983, 2(5):775-779.
Smith et al., “Corticotropin Releasing Factor Receptor 1-Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development,” Neuron, 1998, 20(6):1093-1102.

Affiliated with

Also associated with

Rating

Stresscopins and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stresscopins and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stresscopins and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4251858